TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
Welcome👋to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) September 28, 2023
"We seek it here,we seek it there.."
Aye,we nephrologists seek it everywhere.
Couple of weeks ago, NephJC discussed the intriguing urinary biomarker study for diagnosis of AIN by @dmoledina et al.
✳️#NephJC catch-up✳️of the damned, elusive chase!👇 pic.twitter.com/OsiMjOaKEA